{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"10.5","value":"8.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Time interval in months from date of first treatment until the date of first documented progression","dispersionType":"95% Confidence Interval","groups":[{"description":"Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.","id":"OG000","title":"Bevacizumab + Capecitabine + Oxaliplatin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"39 months","title":"To Determine the Overall PFS for CAPOX and Bevacizumab","type":"SECONDARY","unitOfMeasure":"months"}